Lung Cancer

Company publishes preclinical results describing NC 381, an antitumor agent

Published in Cancer Weekly, December 23rd, 2003

Scientists at Lorus Therapeutics, Inc., have published the results of investigations aimed at characterizing a clotrimazole (CLT) analogue, NC 381.

CLT is an antifungal drug that has demonstrated anticancer activity but, its potential is limited by the presence of high liver toxicity. The goal of the study was to develop a variation or analogue of CLT that maintained the anticancer activity without the toxic side effects.

The results appear in an article entitled, "NC 381, A Novel Anti-cancer Agent, Arrests the Cell Cycle in G₀ -G₁ and Inhibits Lung Tumor Cell Growth In Vitro and In Vivo" in a November electronic version of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-12-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry